Clinical Trial Update: Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL

View source ↗

Summary

Expanded Access Protocol for blinatumomab in pediatric and adolescent patients with relapsed or refractory B-precursor acute lymphoblastic leukemia is no longer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | Status: NO_LONGER_AVAILABLE